Although mitral valve prolapse (MVP) has shown to be associated with thromboembolic complications, the cause of thromboembolic events in those patients is still unknown. The purpose of this study was to evaluate the fibrinolytic activity in MVP patients. The study included 35 consecutive patients (25 women, mean age 25 ±11 years) with echocardiografically documented MVP and 25 age-and sex-matched subjects as a control group. Four of MVP patients have a history of transient ischemic attack (TIA). Global fibrinolytic capacity (GFC), a new technique that examines the effectiveness of the entire fibrinolytic system, was measured. Global fibrinolytic capacity was found to be nonsignificantly increased in MVP patients (3.14 ±1.42 /-g/mL) compared to those in control subjects
Global fibrinolytic capacity was studied in 35 consecutive patients with echocardiographically documented mitral valve prolapse (MVP) and 25 healthy subjects as a control group. Four of MVP patients had a history of transient ishemic attack (TIA). We found that global fibrinolytic activity was similiar in MVP patients without a history of TIA and control subjects. However, MVP patients with a history of TIA had significantly decreased global fibrinolytic activity compared to controls as did MVP patients without a history of TIA. Mitral valve prolapse (MVP) is a common disorder, with prevalence estimates generally ranging from 2.4% to 15% in the general population (2.36 ±1.33 ,ug/mL) (p>0.05). However, in four of these MVP patients who had a history of transient ischemic attack, the GFC level was significantly lower than in patients who have no history of transient ischemic attack (1.67 ±0.6 Ag/mL vs 3.27 ±1.46 (jtg/mL, p=0.003). Furthermore, the GFC levels of these four patients were less than those of controls (p=0.04). These results showed that global fibrinolytic activity was similar in MVP patients without a history of TIA and control subjects. However, MVP patients with a history of TIA had significantly decreased global fibrinolytic activity compared to controls and as well as MVP patients without a history of TIA. Key Words: Mitral valve prolapse-Fibrinolytic capacity-Thromboembolism.
(1-5). Studies examining the association between MVP and stroke in young patients reported conflicting results (1, (6) (7) (8) (9) . Most of the previous studies have reported an association between thromboembolic complications, including acute neurologic events and MVP, especially in young MVP patients (<45 years old), who are less likely than older patients to have atherosclerosis or hypertension as the cause of stroke (1, (6) (7) (8) . However, a recent study disclosed the lack of association between MVP and stroke in young patients (9) .
The pathobiology of increased thromboembolic events in patients with MVP is still unknown. The thrombotic tendency of MVP may be related to the platelet activation due to exposure to an abnormal valvular surface or hemodynamic irregularity or the activation of the coagulation system. However, previous studies widely investigating platelet activation in patients with MVP have yielded inconsistent results (10) (11) (12) (13) (14) (15) (16) (17) . Nevertheless, there are limited number of studies evaluating the components of the fibrinolytic activity in those patients (13, 17, 18) . Therefore, we aimed to assess the fibrinolytic activity in MVP patients with or without neurologic complications. Accordingly, global fibrinolytic capacity (GFC) assay, a new technique that examines the effectiveness of the entire fibrinolytic system, was used to elucidate fibrinolysis in MVP patients with or without transient ischemic attacks (TIA) (19) .
MATERIALS AND METHODS

Subjects
The study included 35 consecutive patients (25 women, 10 men; mean age, 25 ±11 years) with echocardiographically documented MVP. Four of these MVP patients had a history of TIA. These patients were consecutive outpatients seen at our cardiac clinic for asymptomatic cardiac murmur or nonspecific compliants, such as palpitations or atypical chest pain, as well as patients being evaluated for TIA (four patients). The control group consisted of 25 age-and sexmatched subjects who had normal findings on physical examination, resting electrocardiogram, and echocardiography were studied.
Exclusion criteria were cerebrovascular accident within 6 months, chronic infection, diabetes mellitus, cancer, chronic liver disease, renal insufficiency, hypothyroidism, connective tissue disease, deep venous thrombosis, pulmonary embolism, hyperlipidemia, treatment with anticoagulant drugs, or women taking oral contraceptives. Furthermore, patients with previously documented severe mitral regurgitation, other coex-isting valvular lesions, or atrial tachyarrhytmia were also excluded. All patients gave informed consent to participate in the study.
Echocardiographic Study
All subjects underwent standart two-dimensional echocardiography with a commercially available system (Toshiba SSH-160-System, Japan; or Vingmed System 5, Norway) that used a 2.5to 3.5-MHz transducer. The echocardiographic examinations were performed by three experienced cardiologists in blinded manner. Two-dimensional parastemal long-axis, short-axis, and apical fourchamber views were recorded to visualize the anterior and posterior mitral leaflets adequately. Mmode echocardiography was performed according to the recommendations of the American Society of Echocardiography (20) . For two-dimensional echocardiography, selection criteria included marked superior systolic displacement or billowing of one or both mitral leaflets across the saddleshaped mitral anular plane in the parastemal longaxis view, and displacement of the mitral valve leaflet in the apical long-axis view. Systolic bowing of one or both mitral leaflets in the apical fourchamber view only was not considered evidence of mitral valve prolapse (21, 22) . Either doppler or color flow imaging was used to determine the presence of mitral regurgitation (MR). The degree of regurgitation was assesed as the ratio of the maximal regurgitant jet area of the left atrium in the parasternal and apical long-axis and apical fourchamber views and the degree of regurgitation was considered to be trace, mild, moderate, or severe (23) . Additionally all patients with a history of TIA underwent transesophageal echocardiography (TEE) to rule out another cardiogenic source such as patent foremen ovale (PFO). Assay Procedures GFC is a new technique to evaluate the fibrinolytic system (19) . The assay is influenced by tissue-type plasminogen activator (t-PA) levels, urokinase-like plasminogen activator (u-PA), single-chain urokinase-like plasminogen activator (scu-PA), activated protein C (APC), factor VII, plasminogen, plasminogen activator inhibitor-i (PAI-1), and alpha-2 antiplasmin. Therefore, GFC reflects the effectiveness of the entire fibrinolytic system. GFC was measured by semiquantitative macrotex agglutination technique (Diagnostica Stago, Asnieres-sur-Seine, France). The blood samples were obtained from a freeflowing antecubital vein without the use of a tourniquet between 9 and 11 AM. All blood collections were performed after the patient had been in the recumbent position for at least 15 minutes before the procedure and after a 12hour fast. All blood samples were separated by centrifugation, immediately frozen, and stored at -80'C for measurement of adhesion molecules.
Statistical Analysis
The statistical package for social sciences (SPSS) v 7.5 for Windows was used to analyze the data. The Kolmogorow-Smirnow test was used to examine the distribution of numeric variables. Since the variables were normally distributed, parametric tests were used for further statistical analyses. Comparison of plasma GFC levels among the study groups were performed with one-way ANOVA. When these results were statistically significant, they were analyzed by Scheffe's test for multiple comparisons. Correlations among study parameters were measured by Pearson's test. Results were expressed as mean ±SD, and p values less than 0.05 were considered statistically significant. Table 1 indicates the clinical characteristics of patients with MVP as well as the control subjects. There was no significant difference between the two groups in terms of age, sex, left atrial diameter, left ventricular ejection fraction, and platelet count, total cholesterol, and triglyceride levels (p>0.05). All patients were on sinus rhythm. Twenty-seven MVP patients had mild and eight had moderate MR; and three TIA patients had moderate and one had mild MR. In addition, none of the four TIA patients showed PFO in TEE examination.
RESULTS
Comparison of GFC among patients with MVP with or without a history of TIA and control subjects are shown in Fig. 1 . Global fibrinolytic capacity was found to be nonsignificantly increased in MVP patients (3.14 ± 1.42 /ig/mL) compared to those in control subjects (2.36 ± 1.33 jug/mL) (p>0.05). However, in four of these MVP patients who had a history of TIA, the GFC level was significantly lower than in patients who had no history of TIA (1.67 +0.6 /itg/mL vs 3.27 ±+1.46 (jg/mL, p=0.003). Furthermore, the GFC levels of these four patients were less than those of controls (p=0.04).
In patients with mitral valve prolapse, we found no correlation between GFC and age, gender, and severity of mitral regurgitation defined as mild or moderate.
DISCUSSION
To our knowledge, this is the first study assessing GFC in MVP patients. We found similiar GFC levels in MVP patients without a history of TIA and control subjects. However, MVP patients with a history of TIA had significantly decreased global fibrinolytic activity compared to that in the controls and in MVP patients without a history of TIA.
Prothrombin activation fragment F1+2 plasma levels were similar in MVP patients with or without mild-to-moderate MR and in controls (17) . Furthermore, another study demonstrated the prothrombin time, partial thromboplastin time, and factors V and VIII to be normal in patients with MVP, with or without CVD (18) . Both studies suggested that MVP is not responsible per se for blood clotting activation in MVP patients with or without mild-to-moderate MR. Their findings of the activation of blood coagulation in MVP patients is consistent with our results showing decreased GFC in those patients. However, Zuppiroli and associates found highly significant levels of fibrinopeptide a (FPA) and factor VIII-vWF:antigen in MVP patients than in controls with no difference in levels of factor V, XI, XII, and antithrombin-III between groups (13). Accordingly they suggested that patients who had both high levels of FPA and factor VIII-vWF:Ag might have a higher risk factor for thromboembolic episodes because three patients with increments of those parameters had a history of CVD. Likewise, we found decreased global fibrinolytic activity in MVP patients with a history of TIA.
In summary, our study demostrated that MVP patients with a history of TIA had significantly decreased levels of GFC as compared to those in controls and MVP patients without TIA. Our results suggested that it might be worthwhile to perform a GFC test to predict which patients have an increased risk for thromboembolism and subsequently begin therapy to prevent thromboembolic complications in these subgroups of MVP patients.
